Goal and Learning Outcomes

The goal of this course is to educate healthcare professionals in acute care settings about prevention and treatment of COVID-19.
Disclaimer: The COVID-19 pandemic is an ongoing challenge for healthcare workers worldwide. Recommendations will be revised as the situation evolves, treatment guidelines change based on continued research, and restrictions and regulations are updated. Continue to follow local and institutional laws and policies.
After taking this course, you should be able to:
  • List signs and symptoms of COVID-19 infection, including postviral long haul syndrome.
  • Describe how the SARS-CoV-2 virus is transmitted in community and healthcare settings and how it is prevented, diagnosed, and treated.
  • Differentiate vaccinations for COVID-19 approved in the U.S. and list guidelines, side effects, and contraindications for vaccination against COVID-19.

Course Authors

Accreditation Information


In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provider approved by the California Board of Registered Nursing, CEP#13791



Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, New Mexico Board Of Nursing, South Carolina Board Of Nursing and  West Virginia Board Of Examiners For Registered Professional Nurses


Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.



None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.